Cargando…
Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database
T cells are known to be involved in the pathogenesis of rheumatoid arthritis (RA). Accordingly, and to better understand T cells’ contribution to RA, a comprehensive review based on an analysis of the Immune Epitope Database (IEDB) was conducted. An immune CD8+ T cell senescence response is reported...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001542/ https://www.ncbi.nlm.nih.gov/pubmed/36901730 http://dx.doi.org/10.3390/ijms24054296 |
_version_ | 1784904164313137152 |
---|---|
author | Carlé, Caroline Degboe, Yannick Ruyssen-Witrand, Adeline Arleevskaya, Marina I. Clavel, Cyril Renaudineau, Yves |
author_facet | Carlé, Caroline Degboe, Yannick Ruyssen-Witrand, Adeline Arleevskaya, Marina I. Clavel, Cyril Renaudineau, Yves |
author_sort | Carlé, Caroline |
collection | PubMed |
description | T cells are known to be involved in the pathogenesis of rheumatoid arthritis (RA). Accordingly, and to better understand T cells’ contribution to RA, a comprehensive review based on an analysis of the Immune Epitope Database (IEDB) was conducted. An immune CD8+ T cell senescence response is reported in RA and inflammatory diseases, which is driven by active viral antigens from latent viruses and cryptic self-apoptotic peptides. RA-associated pro-inflammatory CD4+ T cells are selected by MHC class II and immunodominant peptides, which are derived from molecular chaperones, host extra-cellular and cellular peptides that could be post-translationally modified (PTM), and bacterial cross-reactive peptides. A large panel of techniques have been used to characterize (auto)reactive T cells and RA-associated peptides with regards to their interaction with the MHC and TCR, capacity to enter the docking site of the shared epitope (DRB1-SE), capacity to induce T cell proliferation, capacity to select T cell subsets (Th1/Th17, Treg), and clinical contribution. Among docking DRB1-SE peptides, those with PTM expand autoreactive and high-affinity CD4+ memory T cells in RA patients with an active disease. Considering original therapeutic options in RA, mutated, or altered peptide ligands (APL) have been developed and are tested in clinical trials. |
format | Online Article Text |
id | pubmed-10001542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100015422023-03-11 Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database Carlé, Caroline Degboe, Yannick Ruyssen-Witrand, Adeline Arleevskaya, Marina I. Clavel, Cyril Renaudineau, Yves Int J Mol Sci Review T cells are known to be involved in the pathogenesis of rheumatoid arthritis (RA). Accordingly, and to better understand T cells’ contribution to RA, a comprehensive review based on an analysis of the Immune Epitope Database (IEDB) was conducted. An immune CD8+ T cell senescence response is reported in RA and inflammatory diseases, which is driven by active viral antigens from latent viruses and cryptic self-apoptotic peptides. RA-associated pro-inflammatory CD4+ T cells are selected by MHC class II and immunodominant peptides, which are derived from molecular chaperones, host extra-cellular and cellular peptides that could be post-translationally modified (PTM), and bacterial cross-reactive peptides. A large panel of techniques have been used to characterize (auto)reactive T cells and RA-associated peptides with regards to their interaction with the MHC and TCR, capacity to enter the docking site of the shared epitope (DRB1-SE), capacity to induce T cell proliferation, capacity to select T cell subsets (Th1/Th17, Treg), and clinical contribution. Among docking DRB1-SE peptides, those with PTM expand autoreactive and high-affinity CD4+ memory T cells in RA patients with an active disease. Considering original therapeutic options in RA, mutated, or altered peptide ligands (APL) have been developed and are tested in clinical trials. MDPI 2023-02-21 /pmc/articles/PMC10001542/ /pubmed/36901730 http://dx.doi.org/10.3390/ijms24054296 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Carlé, Caroline Degboe, Yannick Ruyssen-Witrand, Adeline Arleevskaya, Marina I. Clavel, Cyril Renaudineau, Yves Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title | Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title_full | Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title_fullStr | Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title_full_unstemmed | Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title_short | Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database |
title_sort | characteristics of the (auto)reactive t cells in rheumatoid arthritis according to the immune epitope database |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001542/ https://www.ncbi.nlm.nih.gov/pubmed/36901730 http://dx.doi.org/10.3390/ijms24054296 |
work_keys_str_mv | AT carlecaroline characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase AT degboeyannick characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase AT ruyssenwitrandadeline characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase AT arleevskayamarinai characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase AT clavelcyril characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase AT renaudineauyves characteristicsoftheautoreactivetcellsinrheumatoidarthritisaccordingtotheimmuneepitopedatabase |